Wall Street Zen Upgrades DiaMedica Therapeutics (NASDAQ:DMAC) to Hold

DiaMedica Therapeutics (NASDAQ:DMAC) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Monday.

A number of other analysts also recently issued reports on the company. Craig Hallum lifted their price target on DiaMedica Therapeutics from $8.00 to $11.00 and gave the stock a “buy” rating in a report on Friday, July 18th. Lake Street Capital lifted their price target on DiaMedica Therapeutics from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, July 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of DiaMedica Therapeutics in a report on Friday, August 15th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, DiaMedica Therapeutics presently has an average rating of “Buy” and a consensus price target of $12.33.

DiaMedica Therapeutics Trading Up 3.0%

NASDAQ:DMAC opened at $6.11 on Monday. The firm has a market cap of $315.83 million, a PE ratio of -8.85 and a beta of 1.25. The stock has a fifty day moving average price of $4.43 and a 200 day moving average price of $4.56. DiaMedica Therapeutics has a 12-month low of $3.19 and a 12-month high of $6.82.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.18). Equities analysts forecast that DiaMedica Therapeutics will post -0.59 EPS for the current year.

Insider Buying and Selling at DiaMedica Therapeutics

In other news, major shareholder Jan Stahlberg bought 1,542,857 shares of DiaMedica Therapeutics stock in a transaction dated Wednesday, July 23rd. The stock was acquired at an average cost of $3.50 per share, with a total value of $5,399,999.50. Following the acquisition, the insider owned 6,764,465 shares of the company’s stock, valued at approximately $23,675,627.50. This trade represents a 29.55% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 7.30% of the company’s stock.

Institutional Trading of DiaMedica Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in DMAC. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of DiaMedica Therapeutics in the 2nd quarter valued at about $29,000. Bank of America Corp DE lifted its holdings in shares of DiaMedica Therapeutics by 3,710.3% in the 2nd quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock valued at $33,000 after purchasing an additional 8,274 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in DiaMedica Therapeutics during the 2nd quarter valued at approximately $49,000. Invesco Ltd. purchased a new stake in DiaMedica Therapeutics during the 2nd quarter valued at approximately $54,000. Finally, Intech Investment Management LLC purchased a new stake in DiaMedica Therapeutics during the 2nd quarter valued at approximately $56,000. 10.12% of the stock is owned by hedge funds and other institutional investors.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.